Acquire the license to the best health content in the world
Contact Us

RotaTeq Does Not Seem to Raise Risk of Intussusception

CDC finds no association between the rotavirus vaccine and obstructive bowel condition

FRIDAY, March 16 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention has investigated intussusception cases and found the same rate after use of the RotaTeq vaccine that would be expected to occur without vaccination. There appears to be no association between RotaTeq and the bowel condition, according to a report published in the March 16 issue of the Morbidity and Mortality Weekly Report.

The CDC continues to recommend routine vaccination of infants against rotavirus using three oral doses of RotaTeq at 2 months, 4 months and 6 months of age.

"Monitoring the safety of a new vaccine is very important. The data we have reviewed are reassuring, and we continue to recommend the RotaTeq vaccine," said Anne Schuchat, M.D., director of CDC's National Center for Immunization and Respiratory Diseases, in a statement. "However, we will continue to carefully monitor reports of possible adverse effects associated with the vaccine and will take appropriate action if there proves to be a problem in the future," she added.

The vaccine, manufactured by Merck & Co., has been recommended by the Advisory Committee on Immunization Practices for routine vaccination of infants to protect against rotavirus.

More Information

Physician's Briefing